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Ketamine-Enhanced Psychotherapy:
Preliminary Clinical Observations on its Effects
in Treating Death Anxiety
Ketamine, a dissociative anesthetic commonly used by US physicians, has recently been 
shown to be a powerful anti-depressant and is also capable of eliciting transpersonal experi-
ences that can be transformative. Although currently approved in the US only for use as an 
anesthetic, physicians there can legally prescribe it off-label to treat various psychological/
psychiatric problems and it has been used for these non-anesthetic purposes in Argentina, 
Iran, Mexico, Russia, and the UK, as well as in the US. The literature on using ketamine 
psychotherapeutically is reviewed and two case studies using ketamine-enhanced psycho-
therapy (KEP) for treating death anxiety in terminally-ill people are reported. The potential 
importance of beginning formal research on using KEP during end-of-life for those suffer-
ing death anxiety is emphasized.
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Introduction
The experiential phenomena associated with death remain unknown. Meanwhile, we all know that it is the only certainty in life. Everything that 
lives dies--with no exception. However, human beings 
alone are known to be burdened with the cognitive 
capacity to be aware of our own inevitable mortality and 
to fear what may come afterwards. A central drive of all 
human beings is a self-preservation instinct. Combining 
this instinct with the awareness that death is inevitable 
creates in some of us a paralyzing terror of non-existence, 
which we struggle to overcome through both conscious 
efforts and unconscious defense mechanisms. Our death 
anxiety may be exponentially intensified during the end-
stage of any terminal illness when we face death without 
refuge. Therefore, it may become necessary to help some 
dying people manage death anxiety in such a way that 
it resolves existential and other fears related to the end-
of-life issues. Psychedelic psychotherapy–combined with 
other conventional treatment approaches–may be a 
powerful technique to deal with this challenge, and it 
may also be a useful standalone treatment for patients 
who have had little to no success with more conventional 
approaches.
Numerous clinical research studies of terminally-
ill patients (e.g., with end-stage cancer) treated with 
psychedelic compounds (i.e., primarily lysergic acid 
diethylamide [LSD]) were performed from the late 
1950s to the early 1970s and sometimes demonstrated 
remarkably impressive treatment outcomes (e.g., 
Pahnke, 1968, 1969; Pahnke, Kurland, Goodman, & 
Richards, 1969; Pahnke, McCabe, Olsson, Unger, & 
Kurland, 1969; Pahnke, Kurland, Unger, Savage, & 
Grof, 1970; Pahnke, Kurland, Unger, Savage, Wolf, 
& Goodman, 1970; Richards, Grof, Goodman, & 
Kurland, 1972; Watts, 1973; Richards, Rhead, DiLeo, 
Yensen, & Kurland, 1977; Richards, Rhead, DiLeo, 
Grof, Goodman, DiLeo et al., 1979; Grinspoon & 
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Bakalar, 1979; Richards, 1979/1980; Grof, 1980; Yensen 
& Dryer, 1993/1994; Grob, 1998, 2002; Walsh & 
Grob, 2005).  Kast pioneered pain treatment with LSD 
in patients with terminal cancer by discovering that low 
dose LSD (100 micrograms) brought greater analgesia 
than more widely used medication (such as Dilaudid 
[hydromorphone] and Demerol [meperidine]) and that 
these superior effects lasted for several days as opposed to 
several hours; in addition, he and colleagues documented 
diminished fear of death and significant reduction of 
depressive symptoms (Kast, 1962, 1966a, 1966b; Kast 
& Collins, 1964). Another investigator replicated Kast’s 
findings by treating dying patients with LSD (Cohen, 
1965).
The most comprehensive research on LSD-
assisted psychotherapy on patients with terminal cancer 
was done by Pahnke at the Maryland Psychiatric Research 
Institute from 1965 through the early 1970s; these studies 
asserted that the most powerful results from treatment 
were induced by transpersonal (e.g., spiritual, mystical, 
or peak) experiences (Pahnke, 1968, 1969; Pahnke et 
al., 1969; Pahnke, McCabe et al., 1969; Pahnke et al., 
1970; Pahnke, Kurland et al., 1970). Findings from these 
studies indicated that two-thirds of the LSD treated cancer 
patients had significant improvement with reductions in 
pain, depression, and fear of death.
The final study of that era was done by Grof, 
who used LSD-assisted psychotherapy for treatment 
of 60 patients with terminal cancer (Grof, Goodman, 
Richards & Kurland, 1973). The study measured levels 
of anxiety and depression, and the amount of narcotics 
before and after LSD treatment. The measures also 
included the MMPI and Attitude to Death tests. Grof 
reported that 29 percent of his treated patients showed 
dramatic improvement, with an additional 41.9 percent 
of patients showing moderate improvement. 
The medical use of psychedelic substances was 
subsequently rejected in the US and most other Western 
countries after the onset of the “war on drugs.” This war 
emphasized psychedelics’ potential for harm (Cornwell 
& Linders, 2002) while overlooking their significant 
promise, thus potentially extracting a huge cost on society 
as a whole (Miron, 2004). One of the consequences 
of the suppression of psychedelic research (with the 
exception of ketamine) was an unjustified minimization 
of their potential therapeutic value, even though there 
is voluminous research literature supporting both the 
therapeutic efficacy and safety of psychedelic drugs when 
used by professionals for treating numerous addictive 
disorders and mental health problems (Friedman, 
2006).
However, this prohibition on research has 
changed recently with approval of several US studies of 
psychedelic psychotherapy for treating psychological/
psychiatric problems, including those related to terminal 
illnesses (Friedman, 2006).  One such study at Harbor-
UCLA Medical Center, for treatment of existential anxiety 
in end-stage cancer patients, started in 2004 and was the 
first known legally-conducted study on this topic after 
the decades of prohibition; this study utilizes a psyche-
delic agent psilocybin (4-phosphoryloxy-N.N-dimethyl-
tryptamine) and was developed and funded by the 
Heffter Research Institute (see www.canceranxietystudy.
org). Another  study, pending IRB approval at the 
Mount Sinai Comprehensive Cancer Center in Miami, 
was developed and funded by the Multidisciplinary 
Association for Psychedelic Studies (see www.MAPS.
org) to evaluate the effectiveness of psilocybin-assisted 
psychotherapy for reduction of distress in patients with 
advanced melanoma (personal communication, Sameet 
Kumar, April 4, 2007).
Our paper focuses on the clinical potential 
of another psychedelic drug, ketamine hydrochloride 
(ketamine), which can legally be used by US physicians 
to treat psychological/psychiatric problems including 
anxieties in dying patients. We present two case studies 
on the use of ketamine-enhanced psychotherapy (KEP) 
for anticipated grief resolution (AGR) in patients with 
end-of-life issues. The first case documents a successful 
resolution of anticipated grief outcome after KEP, while 
the second case illustrates some of KEP’s limitations.
Overview of Ketamine
The medication ketamine [2-(2-chlorophenyl)-
2-(methylamino)-cyclohexanone] has many effects 
in the brain, but there is now broad agreement that a 
key action is its noncompetitive antagonism of the N-
methyl-D-aspartate (NMDA) receptor that modulates 
the neurotransmitter glutamate. It produces extremely 
effective analgesia and, for more then 30 years, has been 
commonly used in clinics and hospitals as an anesthetic 
for children, adults, and the elderly due to its rapid onset 
and short duration of action. Also due to its exceptional 
analgesic properties, ketamine is widely used at sub-
anesthetic doses for management of breakthrough pain 
in patients with acute and chronic pain, for treatment of 
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neuropathic pain disorder, ischemic limb pain disorder, 
refractory cancer pain, as an adjunct to standard opioid 
therapy, and as a pediatric sedation tool for use with 
acutely injured children (Petrack, Marx, & Wright, 1996; 
Carr, Goudas, Denman, Brookoff, Staats, Brennen et al., 
2004; Ellis, Husain, Saetta, & Walker, 2004; Green & 
Krauss, 2004; Howes, 2004; McGlone, Howes, & Joshi, 
2004; Rakhee & Milap, 2005; Visser & Schug, 2006). 
Ketamine use is devoid of life-threatening 
side-effects and several instances of unintentional 
administration of overdoses of ketamine–up to ten times 
that usually required–have been followed by prolonged 
but complete recovery (Physician Desk Reference, 
Product Information). All previous clinical studies have 
both established its greater safety (e.g., Green & Krauss, 
2004; White, Way, & Trevor, 1982) and failed to detect 
any long-term impairment as a consequence of its use 
(e.g., Siegel, 1978).  In fact, there is a plethora of recent 
studies investigating the possibility of damage related 
to ketamine with normal, pathological (e.g., patients 
with schizophrenia), and ketamine-abusing volunteers. 
The majority of these studies suggest that ketamine can 
be safely used for treatment of various psychological/
psychiatric problems (Morgan, Mofeez, Brandner, 
Bromley, & Curran, 2004; Karst, Wiese, Emrich, & 
Schneider, 2005; Cho, D’Souza, Gueorgiuieva, Perry, 
Madonick, Karper et al., 2005; Parwani,Weiler, Blaxton, 
Warfel, Hardin, Frey et al., 2005; Holcomb, Medoff, 
Cullen, & Taminga, 2005; Morgan, Rossell, Pepper, 
Smart, Blackburn, Brandner et al., 2006).  
In addition, more than 7,000 published reports 
describe ketamine’s high level of effectiveness in a variety 
of other clinical applications (Shapiro, Wyte, & Harris, 
1972; Reich & Silvay, 1989; Ross & Fochtman, 1995; 
Dachs & Innes, 1997; Bauman, Kish, Baumann, & 
Politis, 1999; Green & Krauss, 2000; Ersek, 2004). 
According to several reports, ketamine in fact prevents 
brain damage from head trauma, strokes, heart attacks, 
epileptic seizures, low oxygen levels, and low blood-sugar 
levels (Shapiro et al., 1972; Weiss, Goldberg, & Choi, 
1986; Rothman, Thurston, Hauhart, Clark, & Solomon, 
1987; Shapira, Lam, Eng, Laohaprasit, & Michel, 1994; 
Hirota & Lambert, 1996). 
The most extensive studies of the biochemical 
aspects of ketamine have been done by a US researcher, 
Krystal, who has been focusing on its effects on 
perceptual and cognitive functioning (Krystal, Karper, 
Seibyl, Freeman, Delaney, Bremner et al., 1994). His 
group of investigators also completed clinical research 
studying the effect of ketamine’s NMDA glutamate 
receptor antagonist response in recovering ethanol-
dependent patients (Krystal, Petrakis, Limoncelli, Webb, 
Gueorgueva, D’Souza et al., 2003). In addition, Krystal’s 
team reported antidepressant effects of ketamine 
(Berman, Cappiello, Anand, Oren, Heninger, Charney 
et al., 2000). These antidepressant effects of ketamine 
have been recently confirmed by a group of government 
investigators at the National Institute of Mental Health 
(Zarate, Singh, Carlson, Brutsche, Ameli, Luckenbaugh 
et al., 2006), documenting a dramatic improvement in 
patients’ mood in a matter of hours among a sample of 
eighteen treatment-resistant patients diagnosed with 
major depressive disorder. It is noted that these newly 
documented powerful antidepressant effects of ketamine 
are of great potential importance.  
One of us (Krupitsky) has collaborated in 
researching the psychopharmacology of ketamine at 
Yale with Krystal (Krupitsky, Burakov, Romanova, 
Grinenko, Fletcher, Petrakis et al., 2001; Krystal, 
Petrakis, Krupitsky, Schütz, Trevisan, & D’Souza, 
2003). Krupitsky also conducted independent studies 
of ketamine psychopharmacology and biochemistry 
(e.g., Krupitsky, Grinenko, Karandashova, Berkaliev, 
Moshkov, & Borodkin, 1990) at the Center for Research 
in Addiction and Psychopharmacology in St. Petersburg, 
Russia, researching the effects of ketamine administration 
on metabolism of biogenic amines.
Although there are both widespread medical 
usages of ketamine as an anesthetic and significant 
ongoing research on many other applications of 
ketamine within the US, we know of no current 
studies examining this medication’s usefulness for the 
treatment of psychological/psychiatric problems. We 
are especially concerned that its potential for treating 
anxieties related to end-of-life issues has been ignored. 
This may be due to the fact that ketamine is seen as a 
potent psychedelic agent. It reliably causes powerful 
alterations in consciousness (e.g., in mood, perception, 
and thought) that naturally occur only during dreaming, 
memory flashbacks, psychoses, and mystical experiences 
(Rumpf, Pedick, Teuteberg, Munchhoff, & Nolte, 1969; 
Grinspoon & Bakalar, 1979; Grinspoon, 1986), and 
this is deemed undesirable in the suppressive climate 
related to the war on drugs. Nevertheless, given that 
many research studies on the clinical effectiveness of 
psychedelics are now resuming in the US (Friedman, 
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2006), it is an opportune time to conduct further studies 
on the effectiveness of ketamine therapy. One fact that 
makes ketamine especially appealing as a psychedelic 
drug for research and clinical practice is that it is currently 
legal for medical practitioners to use in the US now (i.e., 
it can be legally prescribed “off-label”1 by physicians for 
psychotherapeutic purposes). This legal status may greatly 
facilitate the process of getting approval for ketamine’s 
use in formal clinical research, unlike the case with 
other psychedelics that require surmounting numerous 
bureaucratic hurdles. In addition, there is one other 
advantage to ketamine over similar substances, namely 
its effects are of short duration and can be managed 
within the customary timeframe of most psychological/
psychiatric sessions (i.e., in approximately one hour), so 
it can fit into current service delivery systems.
It is also important to emphasize that there 
has been an increase of ketamine abuse (Sputz, 1989; 
Jansen, 1993). When ketamine is used in uncontrolled 
settings recreationally, it can lead to significant medical 
problems, including excessive sedation and respiratory 
depression–especially if combined with depressants like 
alcohol, benzodiazepines, or gamma hydroxybutyrate 
(Ricuarte, 2005). Frivolous use of ketamine may also 
cause impairment of episodic memory and attentional 
functioning (Morgan, Monaghan, & Curran, 2004). 
Therefore, we emphasize that ketamine should never 
be used in any way other than for research or clinical 
applications under the supervision of qualified and 
licensed professionals. 
Transpersonal Effects of Ketamine 
There is no consensual opinion regarding how 
psychedelic substances might work beneficially within 
clinical settings. Most of the researchers view the active 
mechanisms of psychedelic substances solely from a 
biochemical perspective. Ketamine is often considered 
a “psychomimetic” (i.e., causing effects mimicking 
psychoses), prompting some US investigators to use 
ketamine-induced phenomena as a model for studying 
psychoses in experimental research (e.g., Krystal et al.,  
1994). In this model, the psychedelic effects of ketamine 
are seen as undesirable rather than as a potential 
therapeutic mechanism.   
Contrary to this view, we propose that 
ketamine’s powerful psychotherapeutic effect is possibly 
due to its psychedelic-including transpersonal experience 
generating-properties, as it frequently induces in 
sub-anesthetic doses feelings of ego dissolution and 
loss of identity, emotionally intense visions, visits to 
mythological realms of consciousness, vivid dreams and 
memories of possible past incarnations, experience of the 
psychological death and rebirth of the ego, and feelings 
of cosmic unity with humanity, nature, the universe, and 
God. These observable facts were initially described as 
“emergence phenomena” (White et al., 1982) and clearly 
depict a psychedelic experience. These non-ordinary 
states of consciousness offer an additional or alternative 
mechanism of ketamine’s effects over and above purely 
biological explanations.  One of us (Friedman, 2006) 
previously speculated that psychedelic drugs such as 
ketamine are specifically useful due to their transpersonal, 
rather than solely neurobiological, effects. This is also 
congruent with the conclusions of numerous researchers 
that spiritual factors are crucial in treating many 
psychological problems, such as is frequently discussed 
for alcoholism (e.g., Robinson, Brower, & Kurtz, 2003; 
Amodia, Cano, & Eliason, 2005). 
Grof (1980) has developed a comprehensive 
theory of psychedelic psychotherapy from this perspective. 
He concluded that psychedelic substances facilitate 
therapeutic experiences of symbolic death and rebirth of 
the ego, allowing clients to work through deep traumatic 
fixations in their unconscious. Grof successfully applied 
this specific transpersonal psychotherapeutic approach 
to more than 750 patients. He explicitly discouraged 
his clients from analyzing their psychological problems 
and instead assisted them in transcending their inflexible 
maladaptive patterns, placing a strong emphasis on their 
transpersonal growth potential. Although Grof primarily 
used LSD as a psychotherapeutic agent, he acknowledged 
that ketamine holds great promise due to its “affinity for 
positive dynamic systems” (p. 214). He stated that the 
psychoactive effect of ketamine is so powerful that “it 
catapults the patient beyond the point of impasse from 
the previous LSD session, and can make it possible for 
him or her to reach the better level of integration” (p. 
214).
There is another specific advantage that ketamine 
has over other psychedelic substances (i.e., in addition to 
it being legally available through off-label prescription and 
of short duration), namely its well-documented ability to 
reliably replicate near-death experience [NDE] (Domino, 
Chodoff, & Corssen, 1965; Stafford & Golightly, 1967; 
Rumpf et al.,1969; Collier, 1972; Siegel, 1978, 1980, 
1981; Grinspoon & Bakalar, 1979; White et al., 1982; 
Kolp et al.
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Ghoniem, Hinrichs, Mewaldt, & Peterson, 1985; Lilly, 
1988; Sputz, 1989; Kungurtsev, 1991). One of us 
(Jansen) analyzed similarities between ketamine-induced 
transpersonal experience and NDEs in a series of studies, 
concluding that the intramuscular administration of 
150-200 mg of ketamine can reliably reproduce all of 
the features commonly associated with NDEs (Jansen, 
1989a, 1989b, 1990, 1991, 1997, 2001). 
The NDE is an altered state of consciousness 
usually reported by a person who has experienced so-called 
clinical death and has then revived. This is an episode split 
off from the patient’s usual life and marked by unusually 
intense dream-like events. Typical characteristics of an 
NDE include a sense that one is truly dead, a perception 
of separation from the body or out-of-body experience, 
a sense that what is experienced is real, ineffability or a 
sense that the experience is beyond words and cannot be 
described using language, and transcendence of time and 
space (Ring, 1980, 1984; Greyson, 1983).  Some people 
believe that they were actually “in death,” reporting 
that after “dying” they left their body and floated away, 
became enveloped in a dark tunnel, and then entered a 
soothing light; later when they “came back to life,” these 
individuals are reportedly sometimes able to recall the 
events that occurred when they were “dead” (Grof & 
Halifax, 1977; Osis & Haraldsson, 1977).
Greyson reported approximately 70 percent of 
NDEs are accompanied by feelings of calm and peace, 
while about 30 percent of NDEs are very frightening 
(Greyson, 1983; Greyson & Stevenson, 1980).  These 
studies suggest that past memories are often organized 
into a life review and patients often report that, during 
the NDE episode, their entire past flashes before them. 
Transcendent mystical states are also common, with 
visions that include meaningful figures (e.g., parents, 
teachers, partners, friends, etc.) who may be already 
dead or still alive at the time, as well as archetypal images 
(e.g., of angels, Buddha, Christ, Krishna, or any other 
gods and goddesses) representing patients’ belief system. 
The experience of God is often reported as an ocean of 
luminescent white light. After effects of NDEs include: 
decreased fear of death accompanied by increased 
appreciation of life, increased spirituality and concern for 
others, and decreased materialism and competitiveness. 
Two of us (Jansen and Kolp) had personal NDEs from 
natural causes, as well as transpersonal ketamine-induced 
experiences, and can verify the striking similarities 
between both phenomena (i.e., a sense of being dead, out-
of-body experience, feelings of levitation, transcendence 
of time-space continuum, life review, visits of non-
physical realities, encounters with non-corporeal entities, 
ineffability of the experience, etc). It is important to note 
that the effect and phenomenology of NDEs in children 
(who have not yet developed any specific religious 
programming) are similar to NDEs in adults (Morse, 
Conner, & Tyler, 1985).
NDEs are often very transformative and 
can frequently induce positive changes in spiritual 
development and worldview (Ring, 1980, 1984; Ring 
& Valeriano, 1998). There are also numerous anecdotal 
accounts of patients who had a spontaneous remission 
of their illnesses (some of them were even classified as 
“terminal”) after their NDE (Grey, 1985; Morse & Perry, 
1992; Fenwick & Fenwick, 1995; Ring & Valeriano, 
1998; Roud, 1990). Ketamine-induced NDEs appear 
to be equivalent to natural NDEs and may facilitate 
stable recovery by accelerating patients’ psychospiritual 
growth and broadening their worldviews (Krupitsky & 
Grinenko, 1997).
 History of Ketamine in Psychotherapy
 A number of international psychiatric 
investigators have utilized treatment with ketamine 
to create cathartic effects in psychotherapy. In Iran, 
ketamine psychotherapy was shown very effective in 
treating various psychiatric disorders (Khorramzadeh 
& Lofty, 1973). These investigators administered 
ketamine to 100 psychiatric patients with different 
mental health and psychosomatic diagnoses, including 
depression, anxiety, phobias, obsessive-compulsive 
neurosis, conversion reaction, hypochondriasis, hysteria, 
tension headaches, and ulcerative colitis. They reported 
that 91 participants were doing well after six months, 
and 88 remained well after one year. These investigators 
concluded that “ketamine’s abreactive or cathartic effect 
was related to its mind-expanding qualities;” however, 
they did not further specify their findings in clinical 
language. In Argentina, Fontana (1974) used ketamine 
as an adjunct to antidepressive psychotherapy in order 
to facilitate regression to a prenatal level through 
a disintegration and death experience, which was 
followed with a progression experience that was seen as 
similar to a rebirth. He emphasized the advantages of 
ketamine, which made it possible to achieve deep levels 
of regression. In Mexico, Roquet (1974) was the first 
clinician to employ ketamine psychedelic psychotherapy 
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in a group setting. He combined psychoanalytical 
techniques with the healing practices of Mexican Indian 
ceremonies and created a new approach to psychedelic 
psychotherapy that he called “psychosynthesis” (not 
to be confused with the same term used by Assagioli). 
He mainly used this procedure to treat neurotic patients, 
although he described some success with personality 
disorders and selected psychotic patients.
 One of us (Krupitsky) first began using ketamine 
in the former Soviet Union in 1985 for treatment of 
alcoholism. He developed Ketamine Psychedelic Therapy 
(KPT) and treated more than 1,000 patients without 
complications. In one of his many controlled studies, 
nearly 70 per cent of his ketamine-treated patients 
remained abstinent from alcohol during a one-year follow-
up, in contrast to only 24 per cent abstinence achieved 
in a control group treated with a more traditional form 
of therapy (Krupitsky, Grinenko, Berkaliev, Paley, Petrov, 
Moshkov et al., 1992). In a comprehensive clinical 
research review on this subject, Krupitsky (Krupitsky 
& Grinenko, 1997) concluded that KPT is a safe and 
effective treatment for alcoholism and other drug 
dependencies, such as heroin and ephedrine, as well as 
effective for treatment of post-traumatic stress disorder, 
reactive depression, neurotic disorders, and avoidant 
personality disorders, and somewhat effective for the 
treatment of phobic neurosis, obsessive-compulsive 
neurosis, and histrionic personality disorder. 
Krupitsky and his colleagues  (Krupitsky, Burakov, 
Romanova, Dunaevsky, Strassman, & Grinenko, 2002) 
recently conducted a double-blind randomized clinical 
trial comparing the relative effectiveness of high (2.0 mg/
kg IM) to low (0.2 mg/kg IM) dose administrations of 
ketamine for the psychotherapeutic treatment of heroin 
addiction; two-year follow-up data indicated that high 
dose ketamine was more effective. The study reported 
that “high dose KPT produced a significantly greater 
rate of abstinence in heroin addicts within the first 24 
months of follow-up than did low dose KPT” (p. 277). 
The authors also concluded that “high dose KPT brought 
about a greater and longer-lasting reduction in craving 
for heroin, as well as greater positive change in nonverbal 
unconscious emotional attitudes” (p. 278). It appears 
the study’s data represent both a lower rate of recidivism 
and a higher degree of psychological integration.  Recent 
changes in the regulations governing such research in 
Russia have now brought Krupitsky’s pioneering research 
efforts to a halt. 
There was also an intriguing study at the 
University of Cambridge in the UK, in which ketamine 
was used to treat compulsive behavior in young women 
with anorexia nervosa with good results, although the 
publication of this study does not clearly indicate that 
the  clinicians used a psychotherapeutic model (Mills, 
Park, Manara, & Merriman, 1998.) The study used 
infusions of ketamine to treat 15 patients with a long 
history of eating disorder, all of whom were chronic 
and resistant to several other forms of treatment. Nine 
responders showed prolonged remission when treated 
with ketamine infusions. Clinical response was associated 
with a significant decrease in Compulsion score: before 
ketamine, mean +/- SE was 44.0 +/- 2.5; after ketamine, 
27.0 +/- 3.5 (t test, p = 0.0016). 
There have also been various lone practitioners 
in other countries, usually family doctors or psychiatrists, 
who have used ketamine to treat psychological/psychiatric 
problems (see Jansen, 2001.)
Ketamine-Enhanced Psychotherapy
Inspired by Krupitsky, one of us (Kolp) engaged 
in the clinical treatment of alcoholic clients using what 
he called Ketamine-Enhanced Psychotherapy (KEP). His 
approach was explicitly meant to replicate Krupitsky’s 
pioneering work and to extend it into another cultural 
context, the US (note: Kolp is a bi-cultural Soviet-
American psychiatrist, who was originally trained as a 
Soviet psychiatrist, immigrated to the United States in 
1981 and was re-trained as an American psychiatrist). As 
with Krupitsky’s KPT technique, Kolp’s KEP treatment 
explicitly relied on the transpersonal effects of ketamine 
to facilitate psychotherapeutic change. Both researchers 
have recently published their combined observations 
on clinical and empirical research of the effectiveness 
of ketamine-enhanced psychotherapy for treatment of 
alcoholism (Krupitsky & Kolp, 2007).
Once more, although most psychedelic drugs 
are illegal to use in the US even by physicians, ketamine 
is a notable exception because it is readily available to 
physicians as an anesthetic that can be legally used off-
label for psychiatric treatment. Consequently, Kolp 
employed ketamine in his private psychiatric practice in 
the US from the fall of 1996 through the spring of 1999, 
administering it to more than 70 clients. Several of us 
also recently published Kolp’s empirical observations of 
the effectiveness of his KEP for treatment of alcoholism 
(Kolp, Friedman, Young, & Krupitsky, 2006).
Kolp et al.
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During this same period of time, Kolp had an 
opportunity to administer KEP to two patients with 
end-stage cancer. This paper summarizes these patients’ 
responses and provides Kolp’s informal retrospective 
observations on ketamine’s effectiveness for treatment 
of existential anxieties in terminally ill people. We 
emphasize that these clinical administrations were not 
conducted in a formal research context and this paper 
provides the informal retrospective observations on 
ketamine’s effectiveness for treatment of existential 
anxieties in terminally ill people. However, in light of the 
recent resurgence of psychedelic research in the US and 
our plans, as a research team, to now seek institutional 
review board approval and grant funding for formally 
pursuing studies on ketamine’s effectiveness in a number 
of clinical applications including the treatment of death 
anxiety, a reporting of Kolp’s clinical observations is seen 
as warranted. 
Method and Results
KEP was offered to hospice clients for AGR in 
order for terminally ill patients to experience a “death 
rehearsal.” KEP was administered to clients as part of 
a time-limited individual outpatient treatment that 
consisted of five sessions administered in the following 
stages:
Session 1 
Assessment for appropriateness of treatment with 
KEP
Session 2
Establishment of a therapeutic alliance and formation 
of a psychotherapeutic “myth” 
Session 3 
Preparation for the transpersonal experience and 
formulation of the psychospiritual goal for the 
ketamine session 
Session 4
Induction of the transpersonal experience through 
the administration of 150 mg of ketamine 
intramuscularly 
Session 5
Integration of the transpersonal experience 
The course of treatment was structured on a 
weekly basis with one session per week. Sessions 1-
3 and 5 were 75 to 80 minutes long and session 4 
(ketamine-induced near-death experience) was 3 hours 
long. During the first three sessions the patient’s beliefs 
about “afterlife” and attitudes toward the death were 
explored. The patient was told that the psychedelic 
session may induce important insights concerning the 
above beliefs and attitudes. An individually tailored 
“psychotherapeutic myth” was formed during this stage. 
During the fourth session the patient was injected 
with ketamine and instructed to surrender fully to the 
experience. The patient was then exposed to specially 
chosen music (generally, New Age composers). During 
the final session the patient, with the aid of the therapist, 
discussed and interpreted the personal significance of 
the symbolic content of the transpersonal experience. 
This uniquely profound and powerful transpersonal 
experience may help the patient to generate new insights 
and attitudes about the death and dying.
Results from Two Case Studies
In order to illustrate how KEP affected clients 
with end-of-life existential issues, two representative 
case studies are presented. The first case demonstrates a 
success story, while the second case represents a failure 
to resolve anticipated grief. These two case studies are 
informative for understanding how KEP might be 
effective for treatment of anticipated grief resolution, 
and they also shed light on factors that can diminish the 
therapeutic benefits of KEP.
Case Study 1
W developed advanced (stage IV) breast cancer 
when she was 62 years old. By the time she was referred 
to an oncologist the cancer had already spread to the 
bone. She was diagnosed with osteolytic metastases (the 
cancer began eating away the bones of her spine, legs, 
and pelvis), which caused her persistent skeletal pain. The 
oncologist offered her an experimental chemotherapy, 
which W initially accepted. However, W learned that 
the prognosis of metastatic breast cancer is very poor 
and that the treatment with an investigational agent 
does not prolong survival time, which is limited to a few 
months after diagnosis. In addition, she immediately 
developed severe side effects (fatigue, loss of appetite, 
nausea, vomiting, worsening of bone pain) and stopped 
the treatment after the third intravenous administration. 
She was refered to a hospice program for palliative care 
and started treatment with an analgesic (morphine, 20 
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mg. orally, every 4 hours), an anti-anxiety medication 
(Lorazepam, 2 mg. orally, every 6 hours), and an anti-
emetic agent (Metoclopramide, 10 mg. orally, 30 minutes 
before meals and bedtime). It was at this point that she 
requested ketamine-enhanced psychotherapy (KEP) in 
order to experience “death rehearsal.”  
W shared that she was raised as the only child 
in an affluent family and did not have any significant 
childhood traumas. Her mother was Roman Catholic 
and her father was Unitarian Universalist. W initially 
adopted her mother’s religious beliefs, she later changed 
to her father’s views (between ages 8 and 9), and in her 
early 20s she adopted agnosticism as her primary life 
philosophy.
Her substance use history was unremarkable. 
W never smoked tobacco and never used any “hard” 
drugs. She did not start using alcohol until the age of 
21, when she started drinking ETOH very infrequently, 
consuming a glass of a table wine, 1-2 times a year. W 
reported that she never tried any psychedelic drugs, 
including cannabis.  
W identified herself as a “sex and love addict.” 
She shared that she was sexually awakened at the age of 
8 by her 10-year-old cousin, who taught her “the art of 
self-pleasuring.” They practiced mutual masturbation in 
a variety of forms, on a regular basis (frequently daily), 
and, 4 years later, her cousin engaged another participant 
in their sexual explorations, an older boy, who was 
15 year old at that time. That liaison lasted for a year 
until her family moved out of the area. W began dating 
independently at the age of 15 and remained very sexually 
active through her entire life. She never considered her 
sexual behavior to be aberrant or immoral, and she always 
unreservedly enjoyed her sexuality. 
W reported that she devoted her life-long career 
to “a research of human sexuality.” She graduated from 
college with a social science degree at age 22 and started 
traveling extensively around the world, “sampling men of 
all races and colors.” She estimated that she had sex with 
more than 5,000 males and approximately 100 females.
She unintentionally became pregnant at age 
39, giving birth to a healthy daughter whom she 
raised as a single mother. After her daughter started an 
exclusive boarding school, W decided to continue her 
own education as well and completed a doctorate in 
psychology. She became specialized in couples counseling 
and continued practicing her specialty until the time of 
her terminal illness.  
Once W learned her prognosis, she became very 
frightened of her impending death. She also became 
preoccupied with her childhood religious indoctrinations 
and started having uncontrollable fears of “going to the 
Hell” as a punishment for her “morbid sin of lust.” She 
tried returning to her Catholic roots and even participated 
in confession; however, this provided no relief of her 
death anxiety. W remained very fearful and apprehen-
sive, to the point the she developed frequent “attacks of 
terror” several times a day, lasting from several minutes 
to half an hour. W continued having daily panic attacks 
despite ongoing treatment with an anti-anxiety agent.
W started treatment with KEP within one week 
after she terminated her chemotherapy. She spent three 
75 to 80 minutes sessions sharing her life history, spiritual 
views, and beliefs about afterlife. During the preparatory 
stage of her psychotherapy, W was offered the option of 
either decreasing or dicontuing the doses of both CNS 
depressants (Lorazepam and morphine), in order to 
decrease the chance of amnesia and increase the chance 
of a mystical experience during KEP. W agreed with this 
plan and was successfully detoxified from Lorazepam by 
decreasing the dose by 1 mg every 24 hours. She was also 
able to gradually decrease the dose of Morphine from 20 
mg. 6 times a day to 10 mg. 4 times a day. Moreover, she 
completely stopped taking opiates 8 hours prior to the 
KEP session. The half-life of morphine is approximately 
2 hours; therefore, 8 hours of abstinence from the drug 
should have been sufficient time for the opiate to clear 
from the patient’s system.
W received 150 mg of ketamine intramuscularly 
during her fourth session. This dose induced “a near-
death experience,” which lasted for 50 minutes. She 
described the following ketamine-induced transpersonal 
experience: 
My mind hastily left my body and I found myself in the 
heart of nothingness. There weas no space, no time, no 
movement, nothing at all. I knew I was dead and felt 
disappointed that I did not have a life review. As soon as 
I thought about the life review though, I started rapidly 
re-living my entire life. I saw my birth, re-experienced 
my early childhood and adolescence, witnessed my young 
adulthood, and re-lived again my motherhood. 
 I also re-experienced all my sexual encounters and 
love affairs, viewing them not only from my personal 
perspective, but also from the point of view of my 
partners. I was gratified to know that my sexual behavior 
did not hurt my lovers at all. Quite to the contrary, I 
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learned that my lovemaking was the source of an intense 
pleasure for every one of my paramours and that my gift 
of sexual magic enriched their lives.
 I then suddenly transcended into my previous lives 
and was shown that, from the beginning of Creation, 
I was made to be an amorous priestess of love, whose 
destiny was to enlighten people through sexuality. I 
did not feel that I was being judged whatsoever, and 
my shame and guilt were gone instantly. At that very 
moment I was swiftly transported into the brilliant 
light and felt the presence of my Creator. I sensed–with 
a great relief–that Creator is not a god of my mother, 
punishing and wrathful, but a benevolent god of my 
father - a unified force of Nature. I became clearly 
aware that death does not exist and recognized–without 
any doubts–I will be re-born again….
The following week, during her fifth session, 
W happily shared that her persistent pain and recurrent 
panic attacks were completely gone and she was able to 
discontinue taking both morphine and Lorazepam. She 
remained comfortable until her death seven months later 
and did not require treatment with either pain-killers or 
psychotropic medications. Her daughter later reported 
that during the time of her death W was peaceful and 
content, and that she died with dignity and smile on her 
face. 
Case Study 2
L was a 46-year-old male who had developed a 
second attack of cancer. He had his first encounter with 
cancer at age 39, when he was diagnosed with bone 
cancer (chondrosarcoma of the left lower extremity). L 
underwent surgical treatment (amputation of the left leg) 
with follow-up chemotherapy and remained symptom- 
free for almost 7 years.
L developed painless jaundice 2.5 months prior 
to his treatment with ketamine-enhanced psychotherapy 
(KEP), followed by a diagnosis of  advanced pancreatic 
cancer that at time of diagnosis had already became 
metastatic. He learned that for this type of cancer the 
median survival from diagnosis is around 3 to 6 months, 
and that the survival improvement with the combination 
of all available treatments is on the order of less than four 
weeks. L refused the most common surgical treatment 
for pancreatic cancers involving the head of the pancreas 
and declined both chemotherapy and radiotherapy. 
He was accepted by a hospice and it was at that point 
that L requested KEP in order to accept his “dying and 
impending death.”
L was raised by an interfaith couple. His father 
was a Buddhist who shared with L his beliefs in an “afterlife 
existence” and “reincarnation of soul.” His mother was 
an atheist who did not believe in the existence of soul 
and afterlife; she taught L that “we came from the void 
and we are to go into the void.” His parents divorced 
(due to his mother’s infidelity) when L was 12 years old. 
He initially lived with the “party hardy dad” for 2 years 
and then moved to live with the “disciplinarian mom” 
for the next 4 years. He began living independently at 
age 18 and was self-sufficient from that point on.  
At the age of 21, L married an older 34-year-
old woman after the couple had dated for two years. 
They had one son, who was 24-years-old at the time of 
his father’s terminal illness. Father and son had a very 
distant relationship, and L did not talk with his son for 
more than five years. L and his wife divorced six years 
after the consummation of the marriage due to his 
extramarital affairs. After the divorce was finalized, his 
wife was awarded primary custody of the child and L 
became a visitation parent. Once the couple divorced, 
they stopped communicating with each other.
L was a “hermit” and lived in the “deep 
country” in his own rustic dwelling with a breathtaking 
view of a lake and tropical jungles. He had lived alone 
since age 26 and supported himself by growing and 
selling cannabis. Although he had been dealing illegal 
substances for many years, he never had any trouble 
with law or authorities.
L started using alcohol at age 15 and began 
smoking tobacco at 16.  Alcohol was never his “cup of 
tea,” as he used it only a few times a year and eventually 
stopped drinking after age 26. L also stopped smoking 
tobacco when he turned 29 (he used to smoke 4-5 
cigarettes, 3-5 times a week). His drug of choice became 
cannabis, which he started using at age 15 and continued 
to use daily, both smoking and eating, throughout the 
remainder of his life. L was consuming anywhere from 1 
to 2 ounces of cannabis per week. He also “experimented” 
with psychedelic drugs and liked them very much, 
having “tripped” on LSD more than 200 times, “magic 
mushrooms” more than 500 times, and “peyote” more 
than 50 times. On several occasions, he also tried DMT, 
PCP, and MDMA.
At the time of his KEP, L was taking morphine, 
20 mg. 6 times a day, and Xanax, 2 mg. 6 times a day. He 
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was also smoking cannabis, 10-12 “joints” a day, and in 
addition, was eating 3-4 “brownies” a day (he increased the 
consumption of cannabis to more than 2 ounces per week 
and moreover started consuming potent hydroponically-
grown “super weed”). L was offered the option to stop 
cannabis and decrease the doses of both CNS Depressants 
(opiates and Benzodiazepine) in order to increase the 
chance of a positive transcendental experience during 
KEP; however, L opted to continue taking the above 
combination of psychotropic substances.
L had three preparatory sessions in the comfort 
of his own home on a one-to-one basis, each session 
lasting from 75 to 80 minutes. L then undertook KEP, 
with the session lasting about 3 hours. L described his 
ketamine-induced experience as follows: 
As soon as drug started working, my mind separated 
from my body and, in turn, started going into oblivion. 
I realized I am dying and a strong fear of non-
existence completely overwhelmed me. My mind was 
finally gone and I was sucked into an infinite ocean of 
unconditional sorrow. Some part of me–the one of an 
observer–continued existing; however, it began decaying 
as well. I died as a human many times, each time from 
different causes, somehow re-incarnating again, each 
time regressing on a lower level. I then started dying 
and re-incarnating as a mammal, again regressing 
from higher forms to lower ones, next as a bird, after 
that as a fish, and so on, until I became a primordial 
protoplasm, at which point I blacked out. Only when 
the drug stopped working did I recognize that I was still 
alive. It was the worst bummer (a bad “trip”) I’ve ever 
had….
During the last follow-up session L continued 
verbalizing his horror of disintegration all through 
his frightening experience of stepwise regression from 
existence to non-existence. Although he used the word 
“re-incarnation” (most likely a residue of his father’s 
religious beliefs), L utilized this word to describe a slow 
and painful death, not a proof of life after death. He also 
repeatedly stated that he “now knows for sure his mom 
was right when she taught there is no life after death.” 
L was offered additional follow-up sessions; however, 
he declined any further treatment. L continued using 
his drug cocktail in escalating doses and died less than 
2 weeks after our last session–alone, disheveled, and 
soiled–probably from the accidental overdose of the CNS 
depressants.
Conclusion
Due to ketamine’s availability for off-label 
medical use in the US, its short duration of action that 
fits well into the current delivery system, and its long 
history of successful clinical applications in treating a 
variety of mental health problems outside of the US, 
it presents itself as an ideal psychedelic to research the 
effectiveness of psychedelic psychotherapy in the US. 
In addition to biochemical mechanisms that might 
explain its possible efficacy for treating a wide range 
of psychological/psychiatric problems, its presumed 
ability to reliably replicate experiences that are to a 
large extent similar to NDEs provides a plausible 
transpersonal mechanism for its possible efficacy. Due to 
its relationship to NDEs, ketamine may be particularly 
helpful for treating death anxiety in those with terminal 
illnesses, namely by providing an opportunity for a direct 
experience of personal existence as a non-physical being 
that aids decision-making and powerful experiential 
shifts in attitudes toward death and dying. In addition, 
NDEs are well known to induce dramatic psychological 
transformations in people, so ketamine-induced NDEs 
may also have the potential to successfully help dying 
people overcome their existential anxieties as well 
as to treat various psychological problems, addictive 
illnesses, and psychiatric disorders. It should be pointed 
out, however, that we believe a ketamine-induced 
psychedelic experience has no beneficial effect in and of 
itself.  In fact, when ketamine is used in uncontrolled 
settings recreationally, it can lead to significant medical 
problems (Ricuarte, 2005).  We firmly believe that the 
therapeutic relationship, as well as set (i.e., patient’s 
expectations toward the experience) and setting (i.e., 
context surrounding the experience), are paramount to 
the effectiveness of ketamine-enhanced psychotherapy 
(KEP). In order for the KEP sessions to cause positive 
transformative experiences, it is extremely important 
to carefully prepare patients for the KEP session, to 
attentively supervise them during the session, and to 
provide psychotherapy after the session to facilitate 
the integration of the ketamine-induced transpersonal 
experience and to help patients personally accept insights 
gained during the KEP session.  Previous work by 
Krupitsky and Grinenko (1997) demonstrated the added 
value of ketamine above and beyond set and setting; 
the control group of the patients with the same set and 
setting who were injected with a placebo did not gain 
the same benefits as compared to the group of patients 
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receiving ketamine.  For these reasons KEP is a specific 
psychotherapeutic technique structured to incorporate 
the therapeutic relationship, set, and setting to achieve 
maximal benefits.
In a previous paper some of us reported that 
clients who failed to respond well to ketamine treatment 
of alcoholism seemed to have a history of severe control 
issues and/or persistent difficulties in maintaining long-
term interpersonal relationships (Kolp et al., 2006). 
From the first case study presented in this paper, we at 
least partially attribute the woman’s positive treatment 
outcome to the fact that she never tried any psychedelics 
previously (a novelty factor) and had positive 
expectations or set toward it.  She was also willing to 
stop benzodiazepine while decreasing her use of opiates, 
which made the experience stronger. On the other hand, 
from the second case study we hypothesize that the man’s 
negative treatment outcome was due at least in part 
to his extensive history of psychedelic use (i.e., it was 
just “another bad trip” for him) and his unwillingness 
to stop, or at least decrease, his sedative medications 
(benzodiazepine and opioids) before the ketamine 
session. It is noted that both of these CNS depressants 
diminish an individual’s response to ketamine and can 
cause amnesia of the event. They may also negatively 
affect ketamine-induced transpersonal experiences due 
to over-sedation. Therefore, we recommend reducing or 
eliminating use of these substances by patients prior to 
any future therapeutic clinical applications of ketamine. 
Perhaps they should now even be considered as a possible 
contra-indication for ketamine-enhanced psychotherapy. 
In addition to set and setting, we also learned from these 
two patients, as well as from some of our prior research 
with alcohol abusers, that the novelty of the psychedelic 
experience may be salient for successful problem 
resolution. Psychedelics are indeed a unique class of 
drugs that produce intense effects unlike those of other 
drugs–and one’s first “trip” can therefore be a profound 
and life-changing experience (as common wisdom says, 
“there is no second chance for the first impression”).  For 
those with extensive histories of psychedelic use, however, 
there is a diminished chance that a ketamine experience 
will be all that unique and transformative, whereas for 
the novice psychedelic user, given proper set and setting, 
the experience can be profound.  
Consequently we conclude that KEP used 
adjunctively within a carefully crafted set and setting 
does appear to be a promising technique for successful 
resolution of anticipated grief for patients in the US. Of 
course, with informally gathered case studies and no use of 
control groups or blinds (i.e., placebos), nothing definitive 
can be concluded about the generalized effectiveness of 
KEP from these observations. In addition, any possible 
conclusions are further compromised because these data 
were presented and analyzed in a retrospective manner 
without the benefit of written records to substantiate 
them. Nevertheless, based on the solid research on 
ketamine’s usefulness in psychotherapy conducted by 
several international research studies, it is interesting to 
speculate that KEP may be successfully used in this way 
within the US for AGR. Additionally, the case studies 
strongly suggest that a transpersonal explanation for 
KEP’s possible efficacy may be warranted along with 
biochemical explanations.
In order to explore the possible usefulness of 
KEP in the US more fully, beyond what appears to be 
some initial clinical success (and suggested limitations) 
made by Kolp in his practice, we note it is crucial to 
replicate these results in larger, well-controlled studies. 
We have designed the protocol of a prospective single-
site, double-blind, placebo-controlled, randomized, 
parallel group clinical trial of the efficacy of KEP for 
treatment of existential anxieties in hospice patients with 
end-stage cancer. Following patient selection and consent 
procedures, it is planned that clients will receive one 
session with ketamine or placebo on the fourth sessions of 
standard outpatient treatment with outcomes measured 
at baseline before KEP and then one, three and six months 
following discharge. One unique aspect of our planned 
study is that we explicitly hypothesize that transpersonal 
factors, such as changes in level of self-expansiveness 
(Friedman, 1983) and spirituality (MacDonald, 2000), 
are among the essential mechanisms in KEP’s possible 
efficacy and we intend to carefully measure transpersonal 
variables in a standardized fashion, along with other 
important factors.
Another potential area of future research is to 
explore the similarities between ketamine-induced NDEs 
and NDEs triggered by natural causes, such as from 
injuries, strokes, heart attacks, epileptic seizures, low 
oxygen levels, low blood-sugar levels, and other similar 
factors. Perhaps one useful strategy for future study 
would involve the administration of a psychedelic dose of 
ketamine to persons who have previously had a “natural” 
NDE. Psychological measures collected before the 
administration of ketamine in order to determine some 
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baseline information about the past NDE, along with 
the same measures collected after the ketamine-induced 
NDE, could be used to compare both experiences.
The fact that ketamine is an FDA approved 
pharmaceutical and can now be legally prescribed off-
label does circumvent many of the prejudicial concerns 
against conducting research that affects most other 
psychedelics in the US. Ketamine’s lawful availability 
avoids the complex bureaucratic morass that must be 
navigated in researching other psychedelic substances, a 
process in which simply obtaining stringently restricted 
drugs for research purposes can take years to negotiate.  In 
addition, the recent lifting of the ban on formal research 
on psychedelics in the US, which has opened the way for 
a number of important psychedelic studies that are now 
being conducted at major US universities (Friedman, 
2006), leads to an exciting opportunity for expanding 
the already impressive line of therapeutic studies utilizing 
ketamine for treatment of addictive and mental disorders. 
Further, the recent study conducted by investigators 
at the National Institute of Mental Health (Zarate et 
al., 2006) reporting ketamine’s positive effects among 
treatment-refractory patients with major depressive 
disorder adds to the legitimacy of examining ketamine’s 
psychotherapeutic potential. The possible importance of 
psychedelics may lie in their ability to foster transpersonal 
experiences and not just on their neurobiological effects 
(Friedman, 2006).  If transpersonal experiences can 
be further demonstrated both to be reliably produced 
through psychedelics, including ketamine, and to have 
salutary effects, this could dramatically change the way 
that many psychological and psychiatric conditions are 
treated.  This could have broader social implications, 
such as a diminishment of the fervor, stemming in part 
from the fear of powerful transpersonal experiences, that 
at least partially contributes to the war on drugs now 
vigorously pursued within many contemporary Western 
societies.
In regard to using ketamine to treat death anxiety, 
given the current mandate for outcome-based treatments 
that are time-limited as dictated by third-party payers, 
further research into exploring the potential of ketamine 
is very important. In addition, in this era of non-clinical 
constraints based upon financial interests, the possibility 
of developing an effective treatment approach that is cost-
effective, limited to a few sessions, and that facilitates the 
reduction of costly restrictive drugs while simultaneously 
alleviating pain and increasing peace, has tremendous 
appeal. Whether the intrinsic value of psychedelic 
therapies is viewed from the financial aspect or from the 
more humane aspect, we believe there is tremendous 
value in pursuing further research that may alleviate the 
pain of those suffering with the final emotional hurdles 
of surrendering both peacefully and mindfully to the 
inevitable.
Endnotes
1.  “The appropriateness or the legality of prescribing approved 
drug for uses not included in their official labeling is some-
times a cause of concerns and confusions among practi-
tioners. Under the Federal Food, Drug, and Cosmetics 
(FD&C) Act, a drug approved for marketing may be la-
beled, promoted and advertised by the manufacturer only 
for those uses for which the drug’s safety and effectiveness 
have been established and which FDA has approved. These 
are commonly referred as “approved uses.” This means that 
adequate and well-control clinical trials have been reviewed 
and approved by FDA. The FD&C Act does not, however, 
limit the manner in which a physician may use an ap-
proved drug. Once a product has been approved for mar-
keting, a physician may prescribe it for uses or in treatment 
regimens of patient populations that are not included in 
approved labeling. Such “unapproved” or, more precisely, 
“unlabeled” uses may be appropriate and rational in certain 
circumstances and may, in fact, reflect approaches to drug 
therapy that have been extensively reported in medical lit-
erature. The term “unapproved uses” is, to some extent, 
misleading. It includes a variety of situations ranging from 
unstudied to thoroughly investigated drug uses. Valid new 
uses for drugs already on the market are often discovered 
through serendipitous observations and therapeutic in-
novations, subsequently confirmed by well-planned and 
executed clinical investigations. Before such advances can 
be added to the appropriate labeling, however, data sub-
stantiating the effectiveness of a new use or regimen must 
be submitted by the manufacturer to FDA for evaluation. 
This may take time and, without the initiative of the drug 
manufacturer whose product is involved, may never occur. 
For that reason, accepted medical practice often includes 
drug use that is not reflected in approved drug labeling. 
With respect to its role in medical practices, the package 
insert is informational only. FDA tries to assure that pre-
scription drug information in the package insert accurately 
and fully reflects that data on safety and effectiveness on 
which drug approval is based.”  (FDA Notice, 1994, n.p.)
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